Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, has reported significant advancements in its Phase 3 trial for early Alzheimer’s disease and shared its second-quarter 2025 financial results. The trial, identified as NCT06709014, has secured 76 U.S. sites, with 46 actively enrolling patients, 38 patients dosed, and nearly 200 in screening, maintaining an expected 50% screen failure rate. This progress underscores the company's dedication to addressing the urgent need for effective Alzheimer’s treatments.
In addition to trial advancements, Annovis Bio has achieved several milestones, including the presentation of four scientific posters at AAIC 2025, the appointment of a director of biostatistics, and the hosting of a trial update webcast. The company has also strengthened its intellectual property portfolio with global coverage for crystal buntanetap, a key asset in its pipeline.
Financially, Annovis Bio reported a positive trajectory with cash and equivalents totaling $17.1 million as of June 30, 2025, up from $10.6 million at the end of 2024. The company also noted a reduction in quarterly R&D expenses to $5.2 million from $5.8 million in the prior-year period, and a decrease in G&A expenses to $1.1 million from $2.0 million. These improvements contributed to a narrowed net loss per share of $0.32, down from $0.44.
The implications of these developments are significant for patients, investors, and the broader medical community. The progress in the Phase 3 trial brings hope for a potential new treatment for Alzheimer’s disease, a condition affecting millions worldwide. For investors, the improved financial health and strategic advancements position Annovis Bio as a noteworthy player in the biotech sector. More details on the company's progress and financials can be found in the full press release at https://ibn.fm/iO1TH.
